Drug Therapy
- Balancing the myths of corticosteroid therapy
No class of drug has more mythical attributes, interfaces with different medical specialties, or clinical street lore than corticosteroids.
- Steroids in the acutely ill: Evolving recommendations and practice
New information has been generated with regard to what causes critical illness-related corticosteroid insufficiency, how to diagnose it, who should receive corticosteroid treatment, and what regimens to use.
- Managing stage 1 hypertension: Consider the risks, stop the progression
Guidelines on managing patients with stage 1 hypertension and a low 10-year risk of atherosclerotic cardiovascular disease.
- Psychogenic nonepileptic seizure: An empathetic, practical approach
Barriers to care include clinician misperceptions, lack of acceptance of the diagnosis, poor patient engagement with treatment, and lack of access to care.
- Psychogenic nonepileptic seizure: A neurologist’s perspective
Confirming the diagnosis is only the start of the journey. The greater challenge and opportunity lie in how physicians present the diagnosis to the patient and family.
Esophageal adenocarcinoma: A dire need for early detection and treatmentA clinical overview focused on screening, multidisciplinary evaluation, and treatment of early esophageal adenocarcinoma.
- Treating anemia: It’s not just the EPO
Long-term effects of treatment with the new oral inhibitors of prolyl hydroxylase will need to be carefully monitored, as prolyl hydroxylase is a key structural component of diverse proteins.
- Oral hyperpigmentation with weakness and salt-craving
The patient’s primary care physician had attributed the hyperpigmentation on the lower lip and inner cheek to pen ink.
- Glycemic targets in the ICU: A look back, and ahead
Much work is still needed to understand the nuances of glycemic targets in critically ill patients, and to learn how to take advantage of evolving technology to improve glycemic control.
- Glycemic control in the critically ill: Less is more
The authors discuss findings from key trials, metrics of glycemic control, and recommendations of professional societies for target blood glucose ranges in critically ill patients.